Personalis, Inc. announced the publication of results from a major clinical study utilizing its NeXT Personal® test for ultrasensitive detection of molecular residual disease (MRD) in non-small cell lung cancer (NSCLC). The study, published in the journal Cell, analyzed 431 NSCLC patients over a median of more than five years and demonstrated that the NeXT Personal test provides highly sensitive and specific detection of circulating tumor DNA (ctDNA) from diagnosis through long-term surveillance. Key findings include the ability to detect residual and recurrent cancer at multiple stages of patient care, with approximately 36-43% of detections in the ultrasensitive range. Additionally, the study found that patients who did not clear ctDNA during adjuvant chemotherapy were more than five times as likely to experience relapse compared to those who cleared ctDNA. The results have already been published and presented in Cell.